先聲藥業(02096.HK)濫用原料藥銷售支配地位 遭國家市監局罰款逾億元人幣
先聲藥業(02096.HK)公布,今年1月29日,公司收到國家市場監督管理總局出具的《行政處罰決定書》。根據通知,國家市監局認定公司濫用在中國巴曲(酉每)濃縮液原料藥銷售市場的支配地位,實施了沒有正當理由拒絕與相關交易相對人進行交易的行為,違反了反壟斷法的相關條文。國家市監局責令公司停止違法行為,並對公司處以相當於公司截至2019年年底止年度收入2%的罰款約1.007億元人民幣。
公司指,已開始與第三方進行巴曲(酉每)濃縮液原料藥交易,並將根據通知及時繳納行政處罰。考慮到行政處罰的金額,公司認為有關事件及行政處罰不會對公司的業務經營及財務狀況產生任何重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.